Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study

Liraglutide, a long-acting human GLP-1 Analog, given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight without Risk of Hypoglycemia in Patients with Type 2 Diabetes Mellitus Running title: Effect of liraglutide on glycemic control and weight

Liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, has been shown to improve glycemic control in individuals with type 2 diabetes mellitus (T2DM) who fail to achieve blood glucose targets (A1c<7.0%) on metformin and sulfonylureas alone

Liraglutide, a glucagon-like peptide-1 (GLP-1) agonist, has been shown to improve glycemic control in individuals with type 2 diabetes mellitus (T2DM) who fail to achieve blood glucose targets (A1c<7.0%) on metformin and sulfonylureas alone 1. The concurrent use of liraglutide with insulin, however, has not been extensively reported2,3,4. In this year-long observational study we assess the effi...

Liraglutide in the treatment of type 2 diabetes mellitus: clinical utility and patient perspectives

Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant morbidity and mortality. There is good evidence that intensive glycemic control reduces the development and progression of complications in patients with diabetes. In order to achieve glycemic targets, patients often require a combination of oral therapy and/or insulin in addition to lifestyle modification. Unf...

Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain

INTRODUCTION Glucagon-like peptide-1 (GLP-1) receptor agonists are used successfully in the treatment of patients with type 2 diabetes as they are associated with low hypoglycemia rates, weight loss and improved glycemic control. This study compared, in the Spanish setting, the cost-effectiveness of liraglutide 1.8 mg versus lixisenatide 20 μg, both GLP-1 receptor agonists, for patients with ty...

Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting

BACKGROUND Liraglutide is an analog of human glucagon-like peptide-1 (GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is presently used in the treatment of selected patients with type 2 diabetes mellitus (T2DM). OBJECTIVE To assess efficacy and safety of liraglutide in, overweight and obese Indian patients with T2DM. METHODS A single center, prospective, open-labeled, single-arm, o...